The Characteristics of Blood Glucose Profile and the Changes of Hormones in PPDM-C Population
Launched by SHANGHAI CHANGZHENG HOSPITAL · Feb 10, 2025
Trial Information
Current as of June 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how blood sugar levels and certain hormones change in patients with a condition called Post-Pancreatitis Diabetes Mellitus (PPDM-C), which can happen after chronic pancreatitis. The goal is to better understand how these changes in blood sugar and hormone levels are connected. This information could help in managing diabetes for people affected by chronic pancreatitis.
To participate in this study, individuals must be at least 18 years old, be of Chinese descent, and have a confirmed diagnosis of chronic pancreatitis. Importantly, the study is not open for recruitment yet, and potential participants will need to provide blood samples that will be stored for further analysis. Those who have other types of diabetes, recent pancreatic surgery, or severe health issues will not be eligible. If you or someone you know is interested in joining this trial, keep an eye out for when it starts recruiting participants!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female Chinese subjects;
- • Was ≥ 18 years old when signing the informed consent;
- • Patients with complete diagnosis of chronic pancreatitis; ④ Those who voluntarily signed informed consent; ⑤ Those who complete serum samples in multiple centers and put them into storage.
- Exclusion Criteria:
- • Patients with impaired glucose tolerance but undiagnosed diabetes;
- • Patients with T1DM related autoimmune markers or other types of DM;
- • Patients with autoimmune pancreatitis, recurrent acute pancreatitis or acute onset of chronic pancreatitis;
- • Patients who underwent pancreatic surgery or related invasive procedures during treatment;
- • Previous or current malignant tumor; ⑥ Pregnancy or lactation; ⑦ Suffering from severe heart, liver or kidney dysfunction or malignant disease; ⑧ Failure to sign informed consent for cognitive impairment or other reasons.
About Shanghai Changzheng Hospital
Shanghai Changzheng Hospital, affiliated with the Second Military Medical University, is a leading medical institution in China known for its comprehensive clinical services and advanced research capabilities. With a commitment to improving patient outcomes and advancing medical knowledge, the hospital actively engages in clinical trials across various therapeutic areas. Its multidisciplinary team of healthcare professionals collaborates with researchers and industry partners to facilitate innovative studies, ensuring adherence to the highest ethical and regulatory standards. By leveraging its state-of-the-art facilities and expertise, Shanghai Changzheng Hospital aims to contribute significantly to the development of new treatments and therapies that enhance patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported